• Publications
  • Influence
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.
Ciprofloxacin is a broad spectrum fluoroquinolone antibacterial agent. Since its introduction in the 1980s, most Gram-negative bacteria have remained highly susceptible to this agent in vitro;Expand
  • 280
  • 15
Levobupivacaine: a review of its pharmacology and use as a local anaesthetic.
UNLABELLED Based on findings that the cardiotoxicity infrequently observed with racemic bupivacaine shows enantioselectivity, i.e. it is more pronounced with the R(+)-enantiomer, the S(-)-enantiomerExpand
  • 400
  • 10
Sumatriptan. An updated review of its use in migraine.
UNLABELLED Sumatriptan is a selective agonist at serotonin 5-HT1-like receptors, including 5-HT1B/1D subtypes. It is an effective treatment for acute migraine attacks and the injectable form has alsoExpand
  • 134
  • 9
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.
Valsartan competitively and selectively inhibits the actions of angiotensin II at the AT1 receptor subtype which is responsible for most of the known effects of angiotensin II. In clinical trials inExpand
  • 304
  • 8
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
Mycophenolate mofetil is an ester prodrug of the active immunosuppressant mycophenolic acid. It is a noncompetitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase, anExpand
  • 150
  • 8
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
The use of ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well established in patients with nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia andExpand
  • 151
  • 6
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Fludarabine is an antineoplastic agent which has been studied in patients with a variety of lymphoproliferative malignancies. Clinical evidence from comparative studies in chronic lymphocyticExpand
  • 105
  • 6
BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II
Brain‐derived neurotrophic factor (BDNF) governs both the selective survival of neurons during development and the experience‐based regulation of synaptic strength throughout life. BDNF produced aExpand
  • 104
  • 6
Baricitinib: First Global Approval
Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritisExpand
  • 46
  • 6
Infliximab: a review of its use in the management of rheumatoid arthritis.
UNLABELLED Infliximab is a chimaeric monoclonal antibody to human tumour necrosis factor-alpha (TNFalpha). It binds to both soluble and transmembrane forms of TNFalpha at picomolar concentrations inExpand
  • 207
  • 5